Budget Impact Analysis of Subcutaneous Ocrelizumab for Relapsing Multiple Sclerosis in Italy: A Hospital Perspective
Author(s)
Paolo Di Procolo, PhD1, Giuseppina Marrazzo, PhD2, Camilla Porta, MSc3, Lorenzo Pradelli, MD4, Raffaele Palladino, MD PhD5, Vincenzo Brescia Morra, MD6, Marcello Moccia, MD MD(Res) PhD6.
1Integrated Access Manager, Roche spa, Monza, Italy, 2Roche spa, Monza, Italy, 3AdRes srl, Torino, Italy, 4Adres HE&OR, Torino, Italy, 5università degli studi di napoli federico II, Napoli, Italy, 6Multiple Sclerosis Unit, Policlinico Federico II University Hospital, Naples, Italy, Napoli, Italy.
1Integrated Access Manager, Roche spa, Monza, Italy, 2Roche spa, Monza, Italy, 3AdRes srl, Torino, Italy, 4Adres HE&OR, Torino, Italy, 5università degli studi di napoli federico II, Napoli, Italy, 6Multiple Sclerosis Unit, Policlinico Federico II University Hospital, Naples, Italy, Napoli, Italy.
OBJECTIVES: Ocrelizumab administered via intravenous infusion (OCR-IV) is an established disease-modifying therapy (DMT) for patients with relapsing multiple sclerosis (RMS). Its biannual dosing supports improved adherence and persistence, which are key to sustained clinical benefit. A subcutaneous formulation of ocrelizumab (OCR-SC) has been developed to reduce administration time while maintaining comparable safety and efficacy. This study assessed the economic impact of OCR-SC in 2L for the treatment of RMS within the Italian DMT market from the hospital perspective.
METHODS: A dynamic budget-impact model with an underlying Markov structure was developed to estimate the 3-year financial impact of OCR-SC on the budget of Italian hospitals. The number of eligible patients was estimated from the RMS population and projected market share. Efficacy inputs were derived from published literature, with adherence and persistence sourced from Italian real-world data. Unit costs and resource use related to drug administration, monitoring, adverse events, disease management, and relapses were collected from Italian sources. Drug acquisition costs were considered in a scenario analysis.
RESULTS: The estimated annual eligible patient population was 15,870, corresponding to a cumulative total of 47,609 patients over 3 years. The introduction of OCR-SC, with a projected market share increase from 14.8% to 40.2%, led to cost reduction across all cost categories, resulting in total savings of €4.1 million (-1.0%) for Italian hospitals over the 3-year period. Drug administration costs accounted for 42.2% of the economic impact. When including drug acquisition costs, savings increased substantially to €14.5 million.
CONCLUSIONS: The introduction of OCR-SC in Italy can save hospital resources by reducing drug administration time. Enhanced adherence and persistence associated with ocrelizumab, combined with its established efficacy, may further contribute to reducing costs related to relapses and disease progression.
METHODS: A dynamic budget-impact model with an underlying Markov structure was developed to estimate the 3-year financial impact of OCR-SC on the budget of Italian hospitals. The number of eligible patients was estimated from the RMS population and projected market share. Efficacy inputs were derived from published literature, with adherence and persistence sourced from Italian real-world data. Unit costs and resource use related to drug administration, monitoring, adverse events, disease management, and relapses were collected from Italian sources. Drug acquisition costs were considered in a scenario analysis.
RESULTS: The estimated annual eligible patient population was 15,870, corresponding to a cumulative total of 47,609 patients over 3 years. The introduction of OCR-SC, with a projected market share increase from 14.8% to 40.2%, led to cost reduction across all cost categories, resulting in total savings of €4.1 million (-1.0%) for Italian hospitals over the 3-year period. Drug administration costs accounted for 42.2% of the economic impact. When including drug acquisition costs, savings increased substantially to €14.5 million.
CONCLUSIONS: The introduction of OCR-SC in Italy can save hospital resources by reducing drug administration time. Enhanced adherence and persistence associated with ocrelizumab, combined with its established efficacy, may further contribute to reducing costs related to relapses and disease progression.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE97
Topic
Economic Evaluation, Health Technology Assessment, Real World Data & Information Systems
Topic Subcategory
Budget Impact Analysis
Disease
Neurological Disorders